choroidal neovascularization secondary to rare macular diseases
Conditions
Interventions
Case series:intravitreal Conbercept injections
Sponsors
Zhongshan Ophthalimic Center
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Be treated with intravitreal Conbercept injections wihtin a month and be willing to join the trial for at least 1 year; 2. Diagnosis of active CNV secondary to rare macular disease after comprehensive examinations; 3. BCVA must be between = 20 and = 83 letters in the study eye; 4. Aged=18 years.
Exclusion criteria
Exclusion criteria: 1. The patients who want to quit the trial; 2. History of intravitreal treatment with steroids/History of laser photocoagulation/History of intraocular treatment with any anti-angiogenic drugs; 3. Women of child-bearing potential; 4. Active malignancies/History of stroke less than 6 months prior to screening/Uncontrolled systemic inflammation or infection; 5. contraindications to fluorescein angiography (FA), ICGA; 6. patients with choroidal neovascularization caused by AMD/pathological myopia/PCV.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| BCVA;area of CNV; | — |
Countries
China
Contacts
Public ContactWen feng
ZhongShan Ophthalimic Center
Outcome results
None listed